BioLife Solutions (BLFS) Stock Price
BioLife Solutions Price
Revenue has compounded at 30.6% per year over the past 19 years to 96.21 M USD. BioLife Solutions's net margin stands at -12.6%, down from -7.5% several years earlier. Analysts set a median price target of 31.00 USD, implying 19.7% below the current price. Of 15 analysts, 7 rate the stock a buy — an overall Hold consensus.
BioLife Solutions stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
BioLife Solutions business model & stock analysis
Frequently asked questions about BioLife Solutions
BioLife Solutions Inc is a biotech company specializing in developing, manufacturing, and marketing cell and tissue preservation solutions. Their business model revolves around providing innovative products that enhance the effectiveness of biological materials storage and transportation. BioLife Solutions offers a comprehensive portfolio of biopreservation media, enabling improved cell therapies, vaccines, and drug discovery research. By supplying high-quality, proprietary products, BioLife Solutions caters to the needs of various sectors, including regenerative medicine, biobanking, and pharmaceuticals. Through their advanced technologies and solutions, BioLife Solutions Inc aims to support the success of customers in preserving and delivering vital biological materials.
BioLife Solutions Inc is primarily active in the biotechnology industry.
The main competitors of BioLife Solutions Inc in the market include companies such as Thermo Fisher Scientific Inc, Merck KGaA, Teva Pharmaceutical Industries Ltd, and Zimmer Biomet Holdings Inc.
BioLife Solutions Inc, a leading developer and supplier of biopreservation tools for cells and tissues, has a rich history and background. Founded in 1998, the company has been dedicated to improving the quality and extending the shelf life of biological materials. BioLife Solutions Inc specializes in innovative solutions that enable the effective storage, freezing, and transportation of biological samples used in research, clinical trials, and regenerative medicine. With a strong focus on quality and customer satisfaction, BioLife Solutions Inc has become a trusted partner for biotech and pharmaceutical companies worldwide. The company's commitment to continuous innovation and collaboration underscores its position as a leader in the biopreservation industry.
BioLife Solutions Inc. has accomplished several significant milestones. The company has expanded its product portfolio, offering a comprehensive range of innovative biopreservation solutions for cells, tissues, and organs. It has successfully developed and commercialized proprietary technologies to enhance the shelf life and improve the efficacy of biological materials. Furthermore, BioLife Solutions has achieved consistent revenue growth and profitability, demonstrating its strong market presence and customer satisfaction. The company has also forged strategic partnerships with leading organizations, leveraging its expertise to develop cutting-edge biopreservation systems. These achievements highlight BioLife Solutions Inc.'s commitment to advancing biological storage and transportation solutions while delivering value to its customers and stakeholders.
BioLife Solutions Inc is primarily present in the United States. With its headquarters located in Bothell, Washington, the company operates throughout the country. As a leading provider of biopreservation tools and services, BioLife Solutions Inc serves a diverse customer base in the life sciences industry across various states and regions in the United States. The company focuses on supplying innovative bioprocessing solutions and ensuring the quality and preservation of biological materials, such as cells, tissues, and organs, for medical research and therapeutic purposes.
BioLife Solutions Inc is a leading provider of biopreservation tools and services. The company's values center around innovation, quality, and customer satisfaction. With a strong commitment to advancing regenerative medicine and improving patient outcomes, BioLife Solutions Inc focuses on delivering best-in-class biopreservation solutions to its clients. The corporate philosophy of the company revolves around continuous improvement and collaboration with customers, researchers, and industry partners. By offering a wide range of high-performance biopreservation products and leveraging its expertise in cell and tissue preservation, BioLife Solutions Inc strives to contribute to the success and progress of the life sciences industry.
Analysts currently set an average price target of 31.00 USD for the BioLife Solutions stock (median: 31.00 USD), implying -19.7 % versus the latest price. The consensus is based on 15 analyst ratings.
15 analysts currently rate the BioLife Solutions stock: 7 recommend buying, 8 holding and 0 selling. For 2026, analysts expect BioLife Solutions to generate revenue of 114.72 M USD and earnings per share of 0.59 USD.
Converted at the current exchange rate, the BioLife Solutions share trades at 34.42 EUR (38.61 USD).
The BioLife Solutions share (BLFS) is listed on 3 stock exchanges, including: NASDAQ (BLFS), Frankfurt (BJX1.F), Düsseldorf (BJX1.DU).
BioLife Solutions Inc is a company specializing in the production of high-quality biological solutions for customers in the biopharmaceutical and biotechnology industries. The business is divided into two main divisions: BioLife Solutions and Astero Bio. BioLife Solutions focuses on manufacturing proprietary biological solutions for customers in the biopharmaceutical and biotechnology industries, which are used for the stabilization and maintenance of the quality of biological materials such as cells, tissues, and organs. Products include CryoStor, a clinically tested cell cryopreservation solution, and HypoThermosol, a patented cell culture medium specifically designed for the storage and transportation of cell and tissue samples. BioLife Solutions also offers custom formulations for specific applications. The second division, Astero Bio, specializes in the development and manufacturing of temperature control devices for biological storage. The Astero portfolio includes cryogenic storage systems that maintain the quality and integrity of biological samples during storage. Astero Bio also offers biological safety cabinets for laboratories handling pathogenic or toxin-producing organisms. BioLife Solutions and Astero Bio work together to provide their customers with a complete solution for the stabilization and protection of biological materials. The products and solutions of BioLife Solutions and Astero Bio are tailored to meet customer requirements and comply with international standards such as Good Manufacturing Practice (GMP) and the International Organization for Standardization (ISO). BioLife Solutions' business model is based on a value chain, starting with the research and development of new biological solutions and extending to the production and market introduction of these solutions. The solutions and products of BioLife Solutions and Astero Bio are designed to meet customer needs and aim to enhance the efficiency and profitability of companies in the biopharmaceutical and biotechnology industries. BioLife Solutions and Astero Bio have a strong position in the global market for biological solutions, and their products are used by leading companies and institutions worldwide. The company has a strong track record and is committed to further growth and expanding its technological capabilities in the future. The products and solutions of BioLife Solutions and Astero Bio contribute to the progress and development in biotechnology, ultimately improving the quality of life for patients worldwide.
The expected revenue of BioLife Solutions is 114.72 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of BioLife Solutions is 28.65 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of BioLife Solutions is currently 65.55. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the BioLife Solutions stock.
The price-to-sales ratio (P/S) of BioLife Solutions is currently 16.37. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the BioLife Solutions stock.
The Eulerpool Quality Score for BioLife Solutions is 2/10.
The ISIN of BioLife Solutions is US09062W2044. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of BioLife Solutions is A1XCF2. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of BioLife Solutions is BLFS. The ticker symbol is used to trade BioLife Solutions shares on the stock exchange.
BioLife Solutions stock
BioLife Solutions Peer Group
BioLife Solutions Ticker
BioLife Solutions FIGI
All fundamentals and in-depth analysis of BioLife Solutions
Our stock analysis for BioLife Solutions stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of BioLife Solutions. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.